Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Mevion Medical Systems builds compact proton therapy machines that hospitals use to treat cancer.
Proton therapy is a form of radiation treatment that aims a beam of protons at a tumor. Unlike standard X-ray radiation, which passes through the body and exits the other side, protons can be tuned to stop right at the tumor, delivering their energy where it's needed and sparing nearby healthy tissue. The catch has always been size and cost: traditional proton machines are enormous, filling a building and costing well over $100 million. Mevion's pitch is that it shrinks the whole system down so a regular hospital can fit one in a single room.
The company sells these systems to cancer centers and healthcare providers, who pay for the machine plus ongoing service and maintenance. Mevion's signature product is a compact proton therapy system built around a superconducting synchrocyclotron — a small, powerful accelerator that sits right on the rotating gantry that aims the beam. That design is what lets the machine be dramatically smaller than older systems. Customers choose it because it brings proton therapy within reach of community hospitals, not just giant academic medical centers with huge budgets and big buildings. Mevion's story has real drama. It started life as Still River Systems, founded in 2004 near Boston by a team including physicists who wanted to reinvent the proton accelerator. The company burned through years and a lot of capital before shipping its first clinical system, and at one low point its main investor had to step in to keep it alive. It eventually installed systems at respected cancer centers and won regulatory clearances for its compact machines, and in 2025 it announced a deal to combine with a publicly traded partner to raise money and scale up.
The business is capital-intensive and the sales cycle is long, since a hospital buying a proton system is making a multi-million-dollar decision that takes years to close. Mevion competes with larger established players in proton therapy and, indirectly, with conventional radiation machines. The bet is simple: if proton therapy keeps growing and hospitals want it without building a cathedral-sized vault, Mevion's compact design gives it a niche worth owning.
Saved answer · last researched 15 Nov 2026